Paper Details

  1. Home
  2. Paper Details

Assessment of the effectiveness and safety of ethosuximide in the treatment of abdominal pain related to irritable bowel syndrome - IBSET: protocol of a randomised, parallel, controlled, double-blind and multicentre trial.

Author: ArdidDenis, DapoignyMichel, KerckhoveNicolas, PereiraBruno, ScanziJulien

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Irritable bowel syndrome (IBS) is a common digestive disorder causing chronic abdominal pain and bowel problems. While IBS isn't life-threatening, it significantly affects quality of life and is costly to manage. Current treatments are not very effective, and the exact causes of IBS are unknown. Recent research suggests that a type of channel in the nervous system, called a T-type channel, may play a role in IBS pain. This study aims to investigate whether ethosuximide, a medication that blocks T-type channels, can help relieve abdominal pain in people with IBS.
Paper Details　
Original Abstract of the Article :
Irritable bowel syndrome (IBS) is characterised by the association of abdominal chronic pain with bowel habit disorders in the absence of identifiable organic disease. This is the first reason for consultation in gastroenterology, with an estimated prevalence of 10%-15% in industrialised countries. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734298/

データ提供：米国国立医学図書館（NLM）

Ethosuximide: A Potential Treatment for Abdominal Pain in Irritable Bowel Syndrome

Irritable bowel syndrome (IBS), a common gastrointestinal disorder characterized by chronic abdominal pain, affects millions of people worldwide. This research explores the potential therapeutic efficacy of ethosuximide, a medication typically used for epilepsy, in treating abdominal pain associated with IBS. The authors propose a randomized controlled trial to evaluate the effectiveness of ethosuximide in managing IBS-related pain, focusing on the role of T-type channels in pain transmission.

Ethosuximide Shows Promise for IBS-Related Pain

This research suggests that ethosuximide, by blocking T-type channels, could potentially alleviate abdominal pain in patients with IBS. The proposed clinical trial will provide valuable data to further assess the therapeutic potential of ethosuximide for this condition, potentially offering a novel approach to managing IBS-related pain.

Ethosuximide: A Potential Hope for IBS Sufferers

This research offers a glimmer of hope for patients grappling with the debilitating pain of IBS. The proposed trial could lead to a new understanding of IBS-related pain and potentially pave the way for new and more effective treatment options.

Dr. Camel's Conclusion

This research serves as a reminder that the quest for effective treatments for IBS is a journey of discovery. The proposed trial using ethosuximide is a bold step forward, potentially unveiling a new pathway to alleviate the suffering of millions of individuals with this challenging condition.

Date :
  1. Date Completed 2018-05-03
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

28720615

DOI: Digital Object Identifier

PMC5734298

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.